Autor:	Jens W, Eckstein
Rok vydání:	2004
Předmět:	Bridged-Ring Compounds Ovarian Neoplasms Structure-Activity Relationship Clinical Trials Phase II as Topic Clinical Trials Phase I as Topic Drug Evaluation Preclinical Animals Humans Antineoplastic Agents Breast Neoplasms Female Taxoids
Zdroj:	IDrugs : the investigational drugs journal. 7(6)
ISSN:	1369-7056
Popis:	Bayer Corp, under license from Indena SpA, is developing BAY-59-8862, a taxane synthesized from 14beta-hydroxy-10-deacetylbaccatin III, for the potential treatment of cancer.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::d99020941e9b4e4732dc4e9a602c8780 https://pubmed.ncbi.nlm.nih.gov/15197663 Zobrazit plný text záznamu